The present invention describes a pharmaceutical composition whose active ingredient includes conjugates of membrane vesicles ofNeisseria meningitidisand the GM3 ganglioside in a conjugation ratio in excess of proteins, has particular characteristics of size, surface charge and a morphology associated with nano-particulate systems that give it advantageous properties as an immunomodulator, because it induces a convenient and significant reduction of myeloid-derived suppressor cells that has an impacton the response of T lymphocytes and on the survival of patients with tumors. The invention further discloses the use of the pharmaceutical composition disclosed in the treatment of cancer, particularly those cancers where the myeloid-derived suppressor cells (MDSCs) are high； as well as a method of treatment with said composition in cancer patients and a method to select those who will receive said treatment.本發明描述醫藥組成物，該醫藥組成物之活性成分包括腦膜炎奈瑟氏球菌之膜囊泡與GM3神經節苷脂之共軛物，該腦膜炎奈瑟氏球菌之膜囊泡與GM3神經節苷脂係以過量蛋白質之共軛比共軛，該醫藥組成物具有與奈米粒子系統相關之大小、表面電荷和形態之特定特徵，該等特徵使該醫藥組成物擁有作為免疫調節劑之有益性質，因為該醫藥組成物促使對腫瘤患者之T淋巴細胞的反應和存活有影響之髓源抑制細胞合宜且顯著減少。本發明進一步揭示所揭露之醫藥組成物於治療癌症(尤其是其中該髓源抑制細胞(MDSC)數量高之癌症)的用途及使用該組成物以治療癌症患者之方法和選擇將接受該治療之癌症患者之方法。
